Involvement of Raf-1 in chronic δ-opioid receptor agonist-mediated adenylyl cyclase superactivation

Eva V. Varga, Marc Rubenzik, Vanessa Grife, Masano Sugiyama, Dagmar Stropova, William R. Roeske, Henry I. Yamamura

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Abstract

Chronic δ-opioid receptor agonist treatment of Chinese hamster ovary (CHO) cells stably expressing the human δ-opioid receptor (hDOR/CHO) leads to increased cAMP formation after the removal of the agonist (adenylyl cyclase superactivation). We have previously found that at the same time, chronic δ-opioid receptor agonist treatment augments phosphorylation of the adenylyl cyclase VI isoenzyme. Since phosphorylation of adenylyl cyclase VI by Raf-1 protein kinase was recently shown, we tested the role of Raf-1 in adenylyl cyclase superactivation in hDOR/CHO cells. We found that pretreatment of the cells with the selective Raf-1 inhibitor GW5074 (3-(3,5-dibromo-4-hydroxybenzylidene-5-iodo-1,3-dihydro-indol-2-one) (10 μM, 30 min) attenuates chronic deltorphin II-mediated increase in forskolin-stimulated cAMP formation by 40% (n=6, P<0.05). Better understanding of the molecular mechanism of adenylyl cyclase superactivation should aid in the development of analgesics that act longer and have fewer side effects.

Original languageEnglish (US)
Pages (from-to)101-102
Number of pages2
JournalEuropean Journal of Pharmacology
Volume451
Issue number1
DOIs
StatePublished - Sep 6 2002

Keywords

  • Adenylyl cyclase superactivation
  • Human
  • Raf-1
  • δ-Opioid receptor

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Involvement of Raf-1 in chronic δ-opioid receptor agonist-mediated adenylyl cyclase superactivation'. Together they form a unique fingerprint.

Cite this